SV Health Investors Team
Photo of Houman Ashrafian, Managing Partner at SV Health Investors
Houman Ashrafian
SV Health Investors·Managing Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in London
Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in London (Other Lists)
Photo of Alex Badamchi-Zadeh, Senior Associate at SV Health Investors
Alex Badamchi-Zadeh
SV Health Investors·Senior Associate
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in London
Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in BioTech (Series A), Investors in London (Other Lists)
Photo of Josh Baker, Investor at SV Health Investors
Josh Baker
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Boston (MA)
Photo of Michael Balmuth, Managing Partner at SV Health Investors
Michael Balmuth
SV Health Investors·Managing Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Boston (MA)
Photo of Jamil Beg, Partner at SV Health Investors
Jamil Beg
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in United States, Investors in Boston / New England, Investors in Cambridge (MA)
Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in Boston / New England (Other Lists)
Photo of Jonathan Behr, Partner at SV Health Investors
Jonathan Behr
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Cambridge (MA)
Photo of Kate Bingham, Managing Partner at SV Health Investors
Kate Bingham
SV Health Investors·Managing Partner
Sweet spot: $1.5M
Range: $30K - $3.0M
Investors in London
Photo of Darren Black, Partner at SV Health Investors
Darren Black
Sweet spot: $20.0M
Range: $5.0M - $50.0M
Investors in Boston (MA)
Photo of Charles Dunn, Principal at SV Health Investors
Charles Dunn
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in United Kingdom, Investors in London
Investors in BioTech (Series B), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in BioTech (Series A), Investors in BioTech (Series B), Investors in London (Other Lists)
Photo of Tom Flynn, Managing Partner at SV Health Investors
Tom Flynn
SV Health Investors·Managing Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Boston (MA)
Photo of Emily Gaudiano, Senior Associate at SV Health Investors
Emily Gaudiano
SV Health Investors·Senior Associate
Sweet spot: $25.0M
Range: $1M - $150.0M
Investors in United States
EH
Eugene Hill
SV Health Investors·Managing Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Boston / New England, Investors in Boston (MA)
Photo of Ash Khanna, Principal at SV Health Investors
Ash Khanna
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in SF Bay Area (CA)
Investors in Pharmaceuticals (Seed), Investors in BioTech (Series B), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series B), Investors in BioTech (Seed), Investors in San Francisco Bay Area (Other Lists), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series B), Investors in Pharmaceuticals (Series B), Investors in Diagnostics (Series B), Investors in Diagnostics (Seed), Investors in Diagnostics (Series B), Investors in Diagnostics (Seed)
Photo of Dirk Landgraf, Principal at SV Health Investors
Dirk Landgraf
Sweet spot: $5.0M
Range: $1M - $10.0M
Investors in Boston (MA)
Investors in Pharmaceuticals (Seed), Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A), Investors in Drug Delivery (Series B), Investors in Drug Delivery (Seed), Investors in Diverse Investors (Other Lists), Investors in Therapeutics (Series B), Investors in BioTech (Series B), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in BioTech (Series B), Investors in Therapeutics (Series A), Investors in Drug Delivery (Series A), Investors in Drug Delivery (Seed), Investors in Drug Delivery (Series A), Investors in Drug Delivery (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Seed), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed), Investors in Pharmaceuticals (Seed), Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Series B), Investors in Boston / New England (Other Lists)
Photo of Paul LaViolette, Managing Partner at SV Health Investors
Paul LaViolette
SV Health Investors·Managing Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Boston (MA)
Investors in Medical Devices (Seed), Investors in BioTech (Series B), Investors in Medical Devices (Series B), Investors in BioTech (Seed), Investors in Medical Devices (Series A), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in Medical Devices (Seed), Investors in BioTech (Series A), Investors in Medical Devices (Series A), Investors in BioTech (Series B), Investors in Medical Devices (Series B), Investors in Boston / New England (Other Lists)
Photo of Greg Madden, Managing Partner at SV Health Investors
Greg Madden
SV Health Investors·Managing Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Boston (MA)
Photo of Mike Ross, Partner at SV Health Investors
Mike Ross
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in United States, Investors in SF Bay Area (CA), Investors in San Francisco (CA), Investors in San Mateo (CA)
Investors in BioTech (Series B), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in San Francisco Bay Area (Other Lists), Investors in BioTech (Series A), Investors in BioTech (Series B)
Photo of Nikola Trbovic, Managing Partner at SV Health Investors
Nikola Trbovic
SV Health Investors·Managing Partner
Sweet spot: $10.0M
Range: $100K - $15.0M
Investors in New York City
Investors in BioTech (Series B), Investors in BioTech (Seed), Investors in Diverse Investors (Other Lists), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in New York City (Other Lists), Investors in BioTech (Series A), Investors in BioTech (Series B), Investors in BioTech (Pre-seed), Investors in BioTech (Pre-seed)